Controversy Surrounding Anticoagulant Therapy Management in Italy
The suspension of note 101 of the Italian Medicines Agency, which introduces new criteria for the management of anticoagulants in cases of venous thromboembolism, has been extended by 4 months. This decision comes after concerns were raised by scientific societies about the complexity of managing the therapy.
Walter Marrocco, a family doctor of the Federation of General Practitioners (Fimmg) and a drug expert, has weighed in on the controversy, stating that there is no concern about the management of anticoagulant therapies. He explains that patients are being followed by both family doctors and specialists, who are working together to provide answers to the patients and are asking institutions to promote greater collaboration between them.
Marrocco notes that the new suspension of note 101 is a positive development, but emphasizes the importance of using this period to review the criteria together and simplify access to these medicines. He also underscores the need for proper preparation in order to do so effectively.
The doctor further highlights the high interest in the correct use of these drugs, emphasizing the potentially dangerous consequences of pathologies such as deep vein thrombosis and pulmonary embolism. He stresses the importance of having clear and concise guidelines for the management of these conditions.
Commenting on the suspension of note 101, Marrocco emphasizes that family doctors are continuing to treat patients according to the previous criteria and are utilizing a discipline for some cases as indicated by AIFA note 97. However, he acknowledges the need for correct training, information, and sharing in order to effectively manage more complex cases.
In conclusion, Marrocco stresses the need for the revision of note 101 to make the indications for diagnosis and therapy of the guidelines applicable. He argues that the note cannot be an edict that does not take into account the organizational problems of the system.
The controversy surrounding the management of anticoagulant therapies in Italy continues to raise concerns among medical professionals and patients alike, highlighting the need for greater collaboration and clarity in the guidelines for these critical treatments.